Nutramax Laboratories Inc v. Synergylabs LLC

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Nutramax Laboratories, Inc. and Nutramax Laboratories Veterinary Sciences, Inc. (South Carolina)
  • Defendant: SynergyLabs, LLC (Florida)
  • Plaintiff's Counsel: Lash Goldberg Fineberg LLP; Alston & Bird LLP
• Case Identification: 0:26-cv-60930, S.D. Fla., 04/02/2026
• Venue Allegations: Venue is alleged to be proper in the Southern District of Florida because the Defendant, SynergyLabs, LLC, is a Florida company with its principal place of business in the district, thereby establishing residency.
• Core Dispute: Plaintiff alleges that Defendant's "Wuffes Calming Chews" for dogs infringe two patents covering synergistic combinations of natural ingredients formulated to reduce anxiety in mammals.
• Technical Context: The patents operate in the animal health and nutritional supplement sector, addressing a market need for non-pharmaceutical options to manage common behavioral issues like stress and anxiety in pets.
• Key Procedural History: The complaint references pre-suit correspondence in which Plaintiff's counsel notified Defendant of the alleged infringement on February 27, 2026, and subsequent communications in March 2026, which did not resolve the dispute.

Case Timeline

Date	Event
2015-08-31	Priority Date for '384 and '011 Patents
2019-07-02	U.S. Patent No. 10,335,384 Issued
2025-01-14	U.S. Patent No. 12,194,011 Issued
2026-02-27	Plaintiff sends correspondence to Defendant alleging infringement
2026-03-11	Defendant's counsel responds, acknowledging receipt
2026-03-13	Plaintiff's counsel sends follow-up correspondence
2026-03-18	Plaintiff's deadline for Defendant to correct understanding of its role passes
2026-04-02	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,335,384 - "Compositions Comprising Magnolia, Phellodendron, Theanine and/or Whey Protein"

• Patent Identification: U.S. Patent No. 10,335,384 ("'384 Patent"), issued July 2, 2019. Compl. ¶23

The Invention Explained

• Problem Addressed: The patent background describes the prevalence of anxiety, fear, and stress in companion animals, noting that existing pharmaceutical treatments can have undesirable side effects such as sedation and lethargy, and that consumers are increasingly seeking natural alternatives. '384 Patent, col. 1:19-2:6 '384 Patent, col. 2:50-58
• The Patented Solution: The invention is an anxiolytic composition that provides a "multi-modal approach" by combining several natural ingredients-L-theanine, whey protein, an extract of magnolia, and an extract of phellodendron-that are claimed to work synergistically to modulate neurotransmitter systems (e.g., GABA, serotonin) and produce a calming effect without sedation. '384 Patent, abstract '384 Patent, col. 3:9-14 '384 Patent, col. 5:1-11
• Technical Importance: The claimed solution provides a non-pharmaceutical, multi-ingredient formulation for managing animal anxiety, addressing a desire for natural products with fewer side effects than traditional drugs. '384 Patent, col. 3:15-21

Key Claims at a Glance

The complaint asserts infringement of at least claims 1, 3-7, and 9-11. Compl. ¶58

• Independent Claim 1:
  • An anxiolytic composition, comprising a combination of
  • L-theanine,
  • a whey protein,
  • an extract of magnolia, and
  • an extract of phellodendron
  • provided in amounts synergistically effective to modulate one or more neurotransmitters.
• Independent Claim 7: A method for reducing, ameliorating, or treating symptoms of anxiety by administering the combination described in Claim 1 to a mammal.
• The complaint reserves the right to assert additional claims. Compl. ¶61

U.S. Patent No. 12,194,011 - "Compositions Comprising Theanine, Magnolia, and Phellodendron"

• Patent Identification: U.S. Patent No. 12,194,011 ("'011 Patent"), issued January 14, 2025. Compl. ¶26

The Invention Explained

• Problem Addressed: Similar to the '384 Patent, the background addresses the need for effective, non-sedating, natural solutions for managing anxiety and stress in animals. '011 Patent, col. 1:26-2:6
• The Patented Solution: The '011 Patent claims a synergistic combination of L-theanine with extracts of magnolia and phellodendron. Unlike the '384 Patent, the independent claims of the '011 Patent do not require the presence of a whey protein, focusing instead on the synergy between the other active ingredients to modulate neurotransmitters like glutamate and GABA. '011 Patent, abstract '011 Patent, col. 5:5-14
• Technical Importance: This patent protects a core formulation for managing animal anxiety that does not rely on a whey protein component, broadening the scope of protection for the inventors' technology. '011 Patent, col. 3:15-24

Key Claims at a Glance

The complaint asserts infringement of at least claims 1-10 and 13-20. Compl. ¶65

• Independent Claim 1:
  • An anxiolytic composition, comprising a combination of
  • L-theanine,
  • at least one of magnolia and an extract of magnolia, and
  • at least one of phellodendron and an extract of phellodendron
  • in amounts synergistically effective to modulate one or more neurotransmitters.
• Independent Claim 13: A method for reducing, ameliorating, or treating symptoms of anxiety by administering the combination described in Claim 1.
• The complaint reserves the right to assert additional claims. Compl. ¶68

III. The Accused Instrumentality

Product Identification

• Wuffes Calming Chews ("Accused Products"). Compl. ¶3

Functionality and Market Context

• The Accused Products are dog supplements formulated and marketed to alleviate stress and anxiety. Compl. ¶3 The complaint alleges they contain a combination of L-Theanine, Relora® (identified as a blend of extracts of magnolia and phellodendron), and dried whey. Compl. ¶33 Specifically, each chew is alleged to contain 35 mg of L-Theanine and 75 mg of Relora®. Compl. ¶33
• The complaint alleges that the Accused Products are marketed as a functional equivalent to Plaintiff's own Solliquin® product and that marketing materials for the Accused Products cite a clinical study involving Solliquin® to substantiate their own efficacy claims. Compl. ¶3 Compl. ¶¶34-35 The complaint provides a screenshot from a marketing video allegedly showing the Wuffes founder in a manufacturing facility wearing a lab coat with the SynergyLabs logo, offered as evidence that SynergyLabs manufactures the Accused Products. Compl. p. 10

IV. Analysis of Infringement Allegations

'384 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
An anxiolytic composition, comprising	The Accused Product is marketed as a supplement that "promotes relaxation" and is "scientifically-formulated to promote a sense of relaxation and maintain calmness."	¶39	col. 3:31-32
a combination of L-theanine, a whey protein, an extract of magnolia, and an extract of phellodendron	The Accused Product is alleged to contain 35 mg of L-Theanine, an amount of dried whey, and 75 mg of Relora®, which is described as a blend of extracts of magnolia officinalis and phellodendron amurense.	¶33	col. 13:23-25
provided in amounts synergistically effective to modulate one or more neurotransmitters.	The complaint alleges synergy based on marketing claims for the Accused Product that reference a "combined effect" and rely on studies of Plaintiff's Solliquin® product to prove effectiveness, which allegedly demonstrates functional equivalence. A screenshot from the Wuffes website shows marketing claims for the Accused Product that cite the 'Landsberg et al., 2017 - Solliquin Study' to support its efficacy.	¶¶34-35; ¶38	col. 5:26-35

'011 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
An anxiolytic composition, comprising a combination of L-theanine,	The Accused Product contains 35 mg of L-Theanine per chew.	¶33	col. 13:21-22
at least one of magnolia and an extract of magnolia, and at least one of phellodendron and an extract of phellodendron	The Accused Product contains 75 mg of Relora®, which is alleged to be a blend of extracts of magnolia and phellodendron. The complaint includes a marketing image from the Wuffes website stating the ingredients were selected for their 'combined effect,' which Plaintiffs assert is a direct claim of the synergistic efficacy.	¶33; ¶37	col. 13:22-24
in amounts synergistically effective to modulate one or more neurotransmitters.	The complaint alleges synergistic effectiveness based on marketing statements about the "combined effect" of the ingredients and claims that the product "boosts natural calming neurotransmitters, including serotonin and GABA."	¶38; ¶40	col. 5:29-38

Identified Points of Contention

• Scope Questions: A central point of contention may be the meaning of "synergistically effective." The dispute could turn on whether the accused formulation provides a therapeutic result that is greater than the sum of its individual components, and what level of evidence is required to prove such an effect.
• Technical Questions: For the '384 Patent, a key question may be whether the "dried whey" in the Accused Product meets the "a whey protein" limitation of claim 1. The complaint alleges "on information and belief" that the dried whey includes a whey protein, suggesting this may be an area requiring discovery and potential expert testimony, especially in relation to the patent's discussion of alpha-lactalbumin. Compl. ¶33

V. Key Claim Terms for Construction

The Term: "synergistically effective"

• Context and Importance: This term appears in the independent claims of both asserted patents and is foundational to the invention. The infringement analysis for both patents will depend heavily on whether the combination of ingredients in the Accused Product is proven to achieve this synergistic standard, as opposed to merely an additive one.
• Intrinsic Evidence for a Broader Interpretation: The specification provides a general definition of synergy as an "effect wherein a combination of two or more components provides a result which is greater than the sum of the effects produced by the agents when used alone." '384 Patent, col. 5:30-34 This could support a construction that does not require a specific quantitative threshold of synergy.
• Intrinsic Evidence for a Narrower Interpretation: The patent details specific in vivo experiments showing statistically significant effects on neurotransmitter levels (e.g., GABA and serotonin) and behavioral test outcomes that were not seen with individual ingredients. '384 Patent, col. 9:1-12:68 '384 Patent, FIGS. 1-2 A defendant may argue that "synergistically effective" should be construed more narrowly to require the specific types of biochemical or behavioral outcomes demonstrated in the patent's examples.

The Term: "a whey protein" ('384 Patent)

• Context and Importance: Infringement of the '384 Patent hinges on whether the "dried whey" in the Accused Product satisfies this limitation. Practitioners may focus on this term because the complaint alleges the presence of whey protein "on information and belief," indicating it is not confirmed. Compl. ¶33
• Intrinsic Evidence for a Broader Interpretation: The plain language of independent claim 1 recites the general term "a whey protein" without further qualification. '384 Patent, col. 13:23 This may support an argument that the term should be given its ordinary meaning, covering various forms of whey that contain protein.
• Intrinsic Evidence for a Narrower Interpretation: The specification frequently highlights "alpha-lactalbumin" as a key component, and dependent claim 2 explicitly narrows "the whey protein" to a composition that "comprises alpha-lactalbumin." '384 Patent, col. 3:36-37 '384 Patent, col. 13:27-28 A defendant could argue that the specification's focus on this specific component should inform the construction of the broader term in the independent claim.

VI. Other Allegations

• Indirect Infringement: The complaint alleges contributory infringement, stating that SynergyLabs manufactures and distributes the Accused Products knowing they are especially adapted for infringing use, have no substantial non-infringing uses, and are a material part of the invention. Compl. ¶59 Compl. ¶66 The complaint points to marketing and user instructions as actions that cause direct infringement by customers. Compl. ¶59 Compl. ¶66
• Willful Infringement: The complaint alleges willfulness based on both constructive and actual knowledge. It is alleged that SynergyLabs, as a competitor in the pet supplement space, knew or should have known of the Asserted Patents. Compl. ¶50 The complaint further alleges that the marketing for the Accused Products explicitly references Plaintiff's patented Solliquin® product and that Solliquin® products are marked with the patent numbers, providing a basis for knowledge. Compl. ¶¶51-52 Finally, the complaint alleges that Defendant had actual notice of infringement as of a cease and desist letter dated February 27, 2026, but continued its infringing conduct. Compl. ¶43 Compl. ¶53

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of evidentiary proof: what technical evidence will Plaintiff provide to demonstrate that the specific formulation of the Accused Product achieves a "synergistically effective" anxiolytic result, as opposed to a merely additive one, and will that evidence meet the standard required by the patent's claims as construed by the court?
• A key question for the '384 Patent will be one of compositional identity: does the "dried whey" listed as an ingredient in the Accused Product constitute "a whey protein" as claimed, particularly when the patent's specification emphasizes the role of a specific component, alpha-lactalbumin?
• The willfulness analysis may turn on imputed knowledge: to what degree can the marketing activities of Defendant's client, which explicitly referenced Plaintiff's patented product, be used to establish that the Defendant manufacturer knew of or was willfully blind to the high risk of infringement prior to receiving direct notice from the Plaintiff?